vimarsana.com

Latest Breaking News On - Soumya raychaudhuri - Page 2 : vimarsana.com

Four new faculty members join the ranks at the Halıcıoğlu Data Science Institute

Deficient immune cells implicated in TB disease progression

Mestag Therapeutics launches with seed financing of $11 million to develop therapeutics targeting activated fibroblast populations across inflammatory disease and cancer

Published: Apr 21, 2021 - Backed by leading healthcare investors including SV Health Investors - Cambridge, UK, 20 April 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced its launch with $11 million seed financing from healthcare investors SV Health Investors and Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”). The Company’s mission is to develop new medicines for patients by targeting activated fibroblast populations and their role in influencing immune effector cells in disease. Powerful new technologies enable diseased tissues to be analyzed at a single-cell level, and this work has uncovered discrete fibroblast cell sub-populations shared across diseases, acting as “immune sentinels” in perpetuating, and progressing disease. Mestag is building a pipeline of first in class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncolog

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.